Premium
Immunohistochemical expression of MDR1 ‐Pgp 170 in canine cutaneous and oral melanomas: pattern of expression and association with tumour location and phenotype
Author(s) -
Finotello R.,
Monné Rodriguez J. M.,
Vilafranca M.,
Altimira J.,
Ramirez G. A.,
Haines A.,
Ressel L.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12281
Subject(s) - immunohistochemistry , phenotype , expression (computer science) , pathology , association (psychology) , biology , medicine , cancer research , gene , genetics , computer science , psychology , psychotherapist , programming language
Canine melanoma ( CMM ) more commonly affects the oral mucosa and the cutis. CMM shares several features with human melanomas ( HMM ), included resistance to a broad variety of antineoplastic chemotherapy agents. P‐glycoprotein 1 (Pgp) expression is a well‐recognized feature of multi‐drug resistance and the purpose of this study was to investigate its expression in treatment naïve CMM . We also investigated Pgp association with tumour location and histological features. Histology records of CMM were retrieved, including patients from 2012–2014. Twenty‐five cases of CMM were included in this study. Results revealed that Pgp is expressed in CMM and oral tumours were more likely to have a membranous Pgp expression (100%) than cutaneous tumours (66.6%) ( P = 0.010). Cytoplasmic and nuclear Pgp expression could also be identified. Results of this study bring useful data that help in understanding one of the possible mechanisms responsible of intrinsic chemotherapy resistance in canine CMM .